KPTI Oct 2024 2.500 call
| Previous close | 0.7400 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.7400 - 0.7400 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksDown -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
Karyopharm Therapeutics (KPTI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PR NewswireKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 22,050 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of August 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with N
- PR Newswire
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
